Nothing Special   »   [go: up one dir, main page]

DE602007011923D1 - Hepatocytenwachstumsfaktor-(hgf-)bindungsproteine - Google Patents

Hepatocytenwachstumsfaktor-(hgf-)bindungsproteine

Info

Publication number
DE602007011923D1
DE602007011923D1 DE602007011923T DE602007011923T DE602007011923D1 DE 602007011923 D1 DE602007011923 D1 DE 602007011923D1 DE 602007011923 T DE602007011923 T DE 602007011923T DE 602007011923 T DE602007011923 T DE 602007011923T DE 602007011923 D1 DE602007011923 D1 DE 602007011923D1
Authority
DE
Germany
Prior art keywords
hepatocytenwachstumsfaktor
hgf
binding proteins
proteins
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602007011923T
Other languages
English (en)
Inventor
William M Winston
Kirk S Wright
May Han
Lyne Breault
Jie Lin
Bijan Etemad-Gilbertson
Christine Knuehl
Jeno Gyuris
Arnold Horwitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aveo Pharmaceuticals Inc
Xoma Technology Ltd USA
Original Assignee
Aveo Pharmaceuticals Inc
Xoma Technology Ltd USA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aveo Pharmaceuticals Inc, Xoma Technology Ltd USA filed Critical Aveo Pharmaceuticals Inc
Publication of DE602007011923D1 publication Critical patent/DE602007011923D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
DE602007011923T 2006-06-02 2007-06-01 Hepatocytenwachstumsfaktor-(hgf-)bindungsproteine Active DE602007011923D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81071406P 2006-06-02 2006-06-02
US86050906P 2006-11-21 2006-11-21
PCT/US2007/012939 WO2007143090A2 (en) 2006-06-02 2007-06-01 Hepatocyte growth factor (hgf) binding proteins

Publications (1)

Publication Number Publication Date
DE602007011923D1 true DE602007011923D1 (de) 2011-02-24

Family

ID=38802077

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602007011923T Active DE602007011923D1 (de) 2006-06-02 2007-06-01 Hepatocytenwachstumsfaktor-(hgf-)bindungsproteine

Country Status (21)

Country Link
US (5) US7649083B2 (de)
EP (2) EP2027156B9 (de)
JP (3) JP4686634B2 (de)
KR (1) KR101196060B1 (de)
AR (1) AR061171A1 (de)
AT (1) ATE495195T1 (de)
AU (1) AU2007254942B2 (de)
BR (1) BRPI0712222B1 (de)
CA (1) CA2654025C (de)
CY (1) CY1111714T1 (de)
DE (1) DE602007011923D1 (de)
DK (1) DK2027156T3 (de)
HK (1) HK1129395A1 (de)
IL (2) IL195037A (de)
MX (1) MX2008014829A (de)
NO (1) NO345476B1 (de)
NZ (1) NZ573818A (de)
PL (1) PL2027156T3 (de)
PT (1) PT2027156E (de)
SG (1) SG158112A1 (de)
WO (1) WO2007143090A2 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0412885A (pt) 2003-07-18 2006-10-03 Amgen Inc polipeptìdios, agentes de ligação especìficos, moléculas de ácido nucleico e linhas de células isoladas, células hospedeiras, composições e anticorpo ou domìnio de ligação de antìgeno e métodos de tratamento de cáncer e de tumor sólido num paciente, de detecção do nìvel do fator de crescimento hepatócito (hgf) numa amostra, de obtenção de anticorpo e de inibição da ligação de hgf a met e de diminuição ou prevenção da ligação de qualquer um dos agentes de ligação especìficos ao fator de crescimento hepatócito (hgf)
BRPI0712222B1 (pt) * 2006-06-02 2021-10-13 Aveo Pharmaceuticals, Inc. Proteína de ligação isolada que se liga ao fator de crescimento de hepatócito humano (hgf), seu uso e método de produção, ácido nucléico, vetor de expressão, célula hospedeira, e métodos para produzir um polipeptídeo que compreende uma região variável da cadeia pesada de imunoglobulina e para produzir um polipeptídeo que compreende uma região variável da cadeia leve de imunoglobulina
ES2378097T3 (es) * 2006-06-02 2012-04-04 Aveo Pharmaceuticals, Inc. Proteínas de unión al factor de crecimiento de hepatocitos (HGF)
US20080233660A1 (en) * 2007-03-23 2008-09-25 Mu Bioteknik Ab Solid phase labeling method
PL2173379T3 (pl) 2007-07-02 2016-02-29 Oncomed Pharm Inc Kompozycje oraz sposoby leczenia i diagnozowania nowotworu
KR20100097719A (ko) 2007-11-30 2010-09-03 칼로바이오스 파마슈티컬스, 아이엔씨. 슈도모나스 아에루기노사의 ＰｃｒＶ 항원에 대한 항체
KR101609894B1 (ko) * 2008-03-14 2016-04-08 알러간, 인코포레이티드 면역-기반 보툴리눔 독소 세로타입 ａ 활성 검정
MX2010012616A (es) 2008-05-29 2010-12-21 Galaxy Biotech Llc Anticuerpos monoclonales para factor de crecimiento de fibroblastos basico.
LT3290052T (lt) 2008-11-07 2020-02-25 Galaxy Biotech, Llc Monokloniniai antikūnai fibroblastų augimo faktoriaus receptoriui 2
US20120052064A1 (en) 2009-04-17 2012-03-01 Yuuki Ito Anti-hgf antibody combinational cancer therapies
JP2013532627A (ja) 2010-07-01 2013-08-19 武田薬品工業株式会社 ｃＭＥＴ阻害剤とＨＧＦおよび／またはｃＭＥＴに対する抗体との組み合わせ
ES2641916T3 (es) 2010-08-31 2017-11-14 Genentech, Inc. Biomarcadores y métodos de tratamiento
ES2865068T3 (es) 2011-01-14 2021-10-14 Univ California Anticuerpos terapéuticos contra la proteína ROR-1 y métodos para usarlos
WO2013012747A1 (en) 2011-07-15 2013-01-24 Oncomed Pharmaceuticals, Inc. Rspo binding agents and uses thereof
AU2012304362A1 (en) 2011-09-09 2014-03-06 Amgen Inc. Use of c-Met protein for predicting the efficacy of anti-hepatocyte growth factor ("HGF") antibodies in esophageal and gastric cancer patients
SG11201400724SA (en) 2011-09-19 2014-04-28 Genentech Inc Combination treatments comprising c-met antagonists and b-raf antagonists
CA2878868A1 (en) 2012-07-13 2014-01-16 Austin L. Gurney Rspo3 binding agents and uses thereof
KR20150118159A (ko) 2013-02-22 2015-10-21 에프. 호프만-라 로슈 아게 암의 치료 방법 및 약물 내성의 예방 방법
US9732150B2 (en) * 2013-03-14 2017-08-15 Alderbio Holdings Llc Therapeutic use of antibodies to HGF
CA2904743A1 (en) * 2013-03-14 2014-09-25 Alder Biopharmaceuticals, Inc. Antibodies to hgf and compositions containing
US9481725B2 (en) * 2013-03-14 2016-11-01 Alderbio Holdings, Llc Antibodies to HGF and compositions containing
US9062104B2 (en) * 2013-03-14 2015-06-23 Alderbio Holdings Llc Therapeutic use of antibodies to HGF
WO2014166029A1 (zh) * 2013-04-07 2014-10-16 永卓博济(上海)生物医药技术有限公司 针对表皮生长因子受体的抗体
WO2015031578A1 (en) * 2013-08-28 2015-03-05 Abbvie Inc. Hgf assay
EP3122900A1 (de) 2014-03-24 2017-02-01 F. Hoffmann-La Roche AG Krebsbehandlung mit c-met-antagonisten und korrelation desselben mit hgf-expression
KR20170005016A (ko) 2014-05-23 2017-01-11 제넨테크, 인크. MiT 바이오마커 및 그의 사용 방법
US20170247437A1 (en) * 2014-08-15 2017-08-31 Oncomed Pharmaceuticals, Inc. Rspo1 binding agents and uses thereof
WO2016044295A1 (en) 2014-09-16 2016-03-24 Oncomed Pharmaceuticals, Inc. Treatment of fibrotic diseases
WO2017070567A1 (en) * 2015-10-21 2017-04-27 The Research Foundation For The State University Of New York Klebsiella pneumoniae antibodies and methods to treat klebsiella pneumoniae infections
CN114729358A (zh) 2019-08-12 2022-07-08 因特尔纳技术有限公司 涉及miRNA-193a的新疗法
AU2021227002A1 (en) 2020-02-28 2022-09-15 Interna Technologies B.V. miRNA-193a for promoting immunogenic cell death
CN116234814A (zh) * 2020-08-28 2023-06-06 江苏恒瑞医药股份有限公司 用于降低异源多肽末端异质性的信号肽

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
CA2507749C (en) 1991-12-13 2010-08-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
EP1997894B1 (de) 1992-02-06 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Biosynthetisches Bindeprotein für Tumormarker
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US6498144B1 (en) * 1993-10-18 2002-12-24 North Shore - Long Island Jewish Research Institute Use of scatter factor to enhance angiogenesis
US5837676A (en) * 1993-10-18 1998-11-17 Long Island Jewish Medical Center Use of scatter factor to enhance angiogenesis
US5707624A (en) * 1994-06-03 1998-01-13 The Regents Of The University Of Michigan Treatment of Kaposi's sarcoma by inhibition of scatter factor
PT1500329E (pt) 1996-12-03 2012-06-18 Amgen Fremont Inc Anticorpos humanos que se ligam especificamente ao tnf alfa humano
US6872518B2 (en) 1997-09-22 2005-03-29 University Of Rochester Methods for selecting polynucleotides encoding T cell epitopes
US7459536B1 (en) * 1999-11-09 2008-12-02 The United States Of America As Represented By The Secretary, Department Of Health And Human Services HGF-SF monoclonal antibody combinations
EP1539233B1 (de) 2001-07-12 2011-04-27 FOOTE, Jefferson Humanisierte super-antikörper
US20040208876A1 (en) 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
US7220410B2 (en) * 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
BRPI0412885A (pt) * 2003-07-18 2006-10-03 Amgen Inc polipeptìdios, agentes de ligação especìficos, moléculas de ácido nucleico e linhas de células isoladas, células hospedeiras, composições e anticorpo ou domìnio de ligação de antìgeno e métodos de tratamento de cáncer e de tumor sólido num paciente, de detecção do nìvel do fator de crescimento hepatócito (hgf) numa amostra, de obtenção de anticorpo e de inibição da ligação de hgf a met e de diminuição ou prevenção da ligação de qualquer um dos agentes de ligação especìficos ao fator de crescimento hepatócito (hgf)
KR100556660B1 (ko) 2003-11-11 2006-03-10 국립암센터 Ｈｇｆ의 중화가능 에피토프 및 이에 결합하는 중화 항체
EP1885400A4 (de) * 2005-06-02 2011-01-26 Galaxy Biotech Llc Verfahren zur behandlung von hirntumoren durch antikörper
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
ES2378097T3 (es) * 2006-06-02 2012-04-04 Aveo Pharmaceuticals, Inc. Proteínas de unión al factor de crecimiento de hepatocitos (HGF)
BRPI0712222B1 (pt) 2006-06-02 2021-10-13 Aveo Pharmaceuticals, Inc. Proteína de ligação isolada que se liga ao fator de crescimento de hepatócito humano (hgf), seu uso e método de produção, ácido nucléico, vetor de expressão, célula hospedeira, e métodos para produzir um polipeptídeo que compreende uma região variável da cadeia pesada de imunoglobulina e para produzir um polipeptídeo que compreende uma região variável da cadeia leve de imunoglobulina
KR100829972B1 (ko) * 2006-07-14 2008-05-16 재단법인서울대학교산학협력재단 항-ｈｇｆ/ｓｆ 인간화 항체 및 이의 제조방법
KR100881825B1 (ko) * 2007-07-27 2009-02-03 주식회사 하이닉스반도체 반도체 소자 및 그 제조 방법

Also Published As

Publication number Publication date
DK2027156T3 (da) 2011-04-26
WO2007143090A3 (en) 2008-03-13
PT2027156E (pt) 2011-04-18
JP4686634B2 (ja) 2011-05-25
JP2011072318A (ja) 2011-04-14
IL195037A0 (en) 2011-08-01
BRPI0712222A2 (pt) 2012-01-10
PL2027156T3 (pl) 2011-06-30
JP2013090632A (ja) 2013-05-16
US20130203963A1 (en) 2013-08-08
SG158112A1 (en) 2010-01-29
NO345476B1 (no) 2021-02-22
EP2027156B9 (de) 2011-03-30
BRPI0712222B1 (pt) 2021-10-13
ATE495195T1 (de) 2011-01-15
KR101196060B1 (ko) 2012-11-01
US8273355B2 (en) 2012-09-25
AU2007254942A8 (en) 2009-02-05
JP5735476B2 (ja) 2015-06-17
NO20085421L (no) 2009-02-27
US20110229462A1 (en) 2011-09-22
EP2361934A3 (de) 2011-11-02
IL219654A0 (en) 2012-06-28
KR20090027226A (ko) 2009-03-16
US7943344B2 (en) 2011-05-17
US20140178935A1 (en) 2014-06-26
WO2007143090A2 (en) 2007-12-13
AU2007254942A1 (en) 2007-12-13
US7649083B2 (en) 2010-01-19
US8580930B2 (en) 2013-11-12
JP2009539347A (ja) 2009-11-19
AR061171A1 (es) 2008-08-06
AU2007254942A2 (en) 2009-05-28
EP2361934A2 (de) 2011-08-31
EP2027156B1 (de) 2011-01-12
US20100173362A1 (en) 2010-07-08
CA2654025A1 (en) 2007-12-13
CA2654025C (en) 2016-08-02
NZ573818A (en) 2011-09-30
MX2008014829A (es) 2009-01-29
AU2007254942B2 (en) 2011-10-27
CY1111714T1 (el) 2015-10-07
EP2027156A2 (de) 2009-02-25
IL195037A (en) 2015-08-31
HK1129395A1 (en) 2009-11-27
US9096664B2 (en) 2015-08-04
US20080108565A1 (en) 2008-05-08

Similar Documents

Publication Publication Date Title
CY2020009I2 (el) Δεσμευτικοι παραγοντες σκληροστινης
DE602007011923D1 (de) Hepatocytenwachstumsfaktor-(hgf-)bindungsproteine
DK2046826T3 (da) Exendin-fusionsproteiner
DK3339445T3 (da) Interleukin -13 bindende proteiner
DK3118221T3 (da) Proteiner
DK1864998T3 (da) Bindingsmolekyler
DK1999154T3 (da) Fremstillede heterodimere proteindomæner
DK2094292T3 (da) Salpeteroxid-blokeret tværbundet tetramerisk hæmoglobin
DK2194043T3 (da) Fremgangsmåder
DK1888113T3 (da) Tweak-bindende antistoffer
BRPI0814971A2 (pt) Proteína
DE602006012066D1 (de) Daraus
DK1885966T3 (da) Forbedret hoved-t-forbindelse
DK1809660T3 (da) Thymus-specifikt protein
DE502005004418D1 (de) Turbolader
DK2081952T3 (da) Peptider
FI20050547A0 (fi) Side
DK2219663T3 (da) Revers-protein
AT504183A3 (de) Skibindungssystem
FI20041026A0 (fi) Sidontalaite
ITCN20060002A1 (it) Imbiellaggio martino
FI20050349A0 (fi) Sidontalaite
FI20050718A0 (fi) Sidontalaite
FI20050927A0 (fi) Sidontalaite
FI20050009A0 (fi) Sidontalaite